

WHAT IS CLAIMED IS:

1. A substantially pure or recombinant DCMP1 polypeptide exhibiting at least about 85% sequence identity to SEQ ID NO: 2 or 8.

2. A substantially pure or recombinant DCMP2 polypeptide comprising:

a) a polypeptide selected from:

1) Gly Val Ser Glu Leu Gln Glu His Thr Thr Gln Lys Ala
His Leu Gly His Cys Pro His Cys Pro Ser Val Cys Val
Pro (residues 118-144 of SEQ ID NO: 4);

2) Gln Val Ala Thr Leu Asn Asn Asn Ala Ser Thr Glu Gly
Thr Cys Cys (residues 166-181 of SEQ ID NO: 4); or

3) Trp Lys Pro Gly Gln Pro Asp Asn Trp Gln Gly His Gly
Leu Gly (residues 263-277 of SEQ ID NO: 4); or

b) sequence exhibiting both:

1) at least 17 contiguous amino acids from DCMP2v as described in SEQ ID NO: 10; and

2) a lack of a segment of at least 12 contiguous amino acids from FKNGPLPLQS LLQRLRWGPC HLLLWLGLGL LLLVIIC (residues 20-56 of SEQ ID NO: 4).

3. A fusion protein comprising the polypeptide of claim 1 or 2.

4. A binding compound which specifically binds to the polypeptide of claim 1 or 2.

5. The binding compound of claim 4 which is an antibody or antibody fragment.

6. A nucleic acid encoding the polypeptide of claim 1 or 2.

7. An expression vector comprising the nucleic acid of claim 6.

8. A host cell comprising the vector of claim 7.

9. A process for recombinantly producing a polypeptide comprising culturing the host cell of claim 8 under conditions in which the polypeptide is expressed.